{"task_id": "a3218dcff7319db7", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 271/464)", "text": "erapy (cisplatin)\n260\nHuman Immunodeficiency Virus\n\n--- Page 282 ---\nAIDS ASSOCIATED MALIGNANCIES (CONT\u2019D)\nNON AIDS DEFINING\nMALIGNANCIES\nincreased\nincidence of Hodgkin\u2019s lymphoma, multiple myeloma,\nanogenital cancer, testicular cancer (seminoma), and\nbasal cell carcinoma in HIV patients. Lung cancer, color\nectal cancer, melanoma, squamous cell carcinoma of\nskin, and head and neck cancer may also be increased\nEDUCATION, PROPHYLAXIS, AND IMMUNIZATION\nFOR HIV PATIENTS\nEDUCATION AND COUNSELING\npatient MUST be\ntold to reveal HIV status to sexual partners and other\nsupportive individuals. Advise regarding condom use\nand safer sex practices. Risk reduction strategies\nshould be explored for substance abuse (e.g. avoid\nalcohol use that may cause disinhibition), tobacco\nuse, and other social issues. HIV is a chronic disease\nthat can be successfully treated\nPJP PROPHYLAXIS\nfor patients with CD4 <200/\nmm3. Trimethoprim sulfamethoxazole SS 1 tab PO\ndaily, or trimethoprim sulfamethoxazole DS 1 tab PO\ndaily, or trimethoprim sulfamethoxazole DS 1 tab PO\nthree times a week. If allergic, desensitize or use dapsone\nTOXOPLASMOSIS\nPROPHYLAXIS\nfor\npatients\nwith positive Toxoplasma serology and CD4 <100/\nmm3. Trimethoprim sulfamethoxazole DS 1 tab PO\ndaily. If allergic, dapsone plus pyrimethamine plus\nfolinic acid are alternatives\nMAC PROPHYLAXIS\nfor patients with CD4 <50/\nmm3. Azithromycin 1200 mg PO once weekly\nHISTOPLASMOSIS\nPROPHYLAXIS\nfor\npatients\nwith CD4 <150/mm3 and living in endemic area.\nItraconazole 200 mg PO daily\nTB PROPHYLAXIS\nfor patients with positive tuber\nculin skin test reaction (induration \u00035 mm) and not\ntreated for TB previously. Isoniazid 5 mg/kg/day PO\ndaily to max 300 mg/day, or 900 mg TIW \u00059 months.\nRifampin 600 mg PO daily \u00054 month restricted to\nexposures to INH resistant, RIF susceptible isolates.\nShould be followed by a TB specialist\nVACCINATIONS\n\u0002\nGIVE\npneumococcal vaccine every 5 years, hepa\ntitis B vaccine (if non immune), hepatitis A vaccine\n(if non immune and especially if homosexual),\ninfluenza vaccine annually\n\u0002\nGENERALLY AVOID\nlive vaccines (oral polio, vari\ncella, measles mumps rubella, or yellow fever\nimmunizations)\nRelated Topics\nHepatitis B (p. 130)\nHepatitis C (p. 131)\nHIV in Pregnancy (p. 413)\nNeedle Stick Injury (p. 269)\nTuberculosis (p. 250)\nANTIRETROVIRAL THERAPY FOR HIV PATIENTS\nNUCLEOSIDE AND NUCLEOTIDE REVERSE TRAN\nSCRIPTASE INHIBITORS (NRTI)\nzidovudine (ZDV,\nAZT), stavudine (d4T), didanosine (ddI), lamivudine\n(3TC), abacavir (ABC), tenofovir (TDF), and emtricita\nbine (FTC). Major side effects include hepatic steatosis,\nlactic acidosis, neuropathy, anemia, pancreatitis, and\nrenal disease\nNON NUCLEOSIDE\nREVERSE\nTRANSCRIPTASE\nINHIBITORS (NNRTI)\nefavirenz (EFV), nevirapine\n(NVP), etravirine (ETR). Major side effects include\nrash, Stevens Johnson syndrome, hepatitis, and\nCNS complications\nPROTEASE INHIBITORS (PI)\nsaquinavir (SQV), indi\nnavir (IDV), nelfinavir (NFV), lopinavir ritonavir (LPV/\nRTV), fosamprenavir (FPV), atazanavir (ATV), tiprana\nvir (TPV), and darunavir (DRV). Major side effects\ninclude hyperglycemia, fat redistribution syndrome,\ninsulin resistance, and GI intolerance\nINTEGRASE INHIBITORS\nraltegravir\nFUSION INHIBITOR (FI)\nenfuvirtide (T 20)\nCCR5 ANTAGONIST\nmaraviroc\nEXAMPLES OF PREFERRED HIGHLY ACTIVE ANTI\nRETROVIRAL THERAPY (HAART) REGIMENS\n\u0002 NRTI (tenofovir plus emtricitabine) plus NNRTI\n(efavirenz)\n\u0002 NRTI (tenofovir plus emtricitabine) plus PI (ataza\nnavir/ritonavir or darunavir/ritonavir)\n\u0002 NRTI (tenofovir plus emtricitabine) plus integrase\ninhibitor (raltegravir)\nTHERAPEUTIC DECISIONS IN HIV\nGOALS OF HIV THERAPY\ndurable suppression of\nHIV viral load to undetectable levels, reduction in HIV\nrelated morbidity, improvement in quality of life,\nprolongation of survival, restoration of immune func\ntion, and prevention of HIV transmission\nAPPROACH\nstart treatment in all symptomatic\npatients and in asymptomatic patients if CD4 <350/\nmm3. Treatment should be considered for CD4\nbetween 350 and 500/mm3 and is optional for\nthose >500/mm3. Rapidly declining CD4 counts\n(>100/mm3/year) or baseline viral loads >100,000\ncopies/mL increase the urgency of treatment. Initiate\nHIV treatment regardless of CD4 in pregnancy, HIV\nnephropathy, and in those with HBV when therapy\nfor HBV is indicated. A commitment to lifelong treat\nment and adherence is essential prior to initiating\ntherapy. HIV therapy is increasingly complex and\nshould only be undertaken by those with expertise\nin HIV management\nRESPONSE\nsuccessful if viral load # by 2 logs after 8\nweeks and # to <50 copies/mL after 6 months of\ntherapy. Need to continue therapy or may develop\nviral load rebound/drug resistance. If failure, consider\nHuman Immunodeficiency Virus\n261", "text_length": 4734, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 271/464)", "type": "chunk", "chunk_index": 270, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.619529", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.620239", "status": "complete", "chunks_added": 3}